

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Meissner et al.

Application Number: 09/393,023


Group Art Unit: 1643

Filed: September 9, 1999

Examiner: TBA

Title: Human Cripin Growth Factor

Attny. Docket No. PF200D1



STATEMENT UNDER 37 C.F.R. 1.821 and 1.825

Assistant Commissioner For Patents
Washington, D.C. 20231

Sir:

Applicants hereby certify under 37 C.F.R. §§1.821(f) and 1.825(a) and (b) that the substitute sequence listing pages filed herein are identical to the computer readable form submitted herewith. Support for the amendment to the paper copy of the substitute sequence listing is found at page 4, lines 12-14 and original claims 3 and 12.

Moreover, applicants hereby certify under 37 C.F.R. §§1.821(g) and 1.825(a) that the substitute sequence listing contains no new matter.

No fee is believed due in connection with this submission. However, should a fee be required, the Assistant Commissioner is hereby authorized to charge such fee to Deposit Account No. 08-3425. A duplicate of this sheet is enclosed.

Respectfully submitted

A handwritten signature in black ink, appearing to read "Michelle S. Marks".

Michelle S. Marks (Reg. No. 41,971)
Attorney for Applicants

Date: 12-7-99

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
(301) 610-5761 (telephone)

MSM/mbp